Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Substance-Related Disorders
Open-data reference.
54 US clinical trials · 15 currently recruiting
Active & Recent Trials
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
National Institute on Drug Abuse (NIDA)
NCT06676059
First Face Training Evaluation in Tribal Communities
Cambridge Health Alliance
NCT05998005
Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
Emory University
NCT05910580
Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program
RTI International
NCT06236100
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
University of Utah
NCT06387290
Disrupting SRFOH to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions
Chestnut Health Systems
NCT06560866
Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families
We The Village
NCT06685003
Whole Health in VA Mental Health: Omnis Salutis
VA Office of Research and Development
NCT05400252
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center
NCT06548490
Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
University of Maryland, College Park
NCT05973838
Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment
University of New Mexi
NCT05489068
Understanding the Role of Doulas in Supporting People With PMADs
University of Montana
NCT05763537
Expression of Stress Markers During Meth Treatment (EXPRESS+)
University of California, Los Angeles
NCT05558345
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Virginia Commonwealth University
NCT05886582
Feasibility of the 5-Step Method in the U.S.
Villanova University
NCT06565429
Scalable Digital Delivery of Evidence-based Training for Family to Maximize Treatment Admission Rates of Opioid Use Disorder in Loved Ones
We The Village
NCT05666856
Socializing a Science-Based Digital Therapeutic for Substance Use Disorders
Square2 Systems
NCT05648786
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Yih-Ing Hser
NCT06023459
Maternal Brain Imaging in Opioid Use Disorder
Indiana University
NCT06008990
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
University of Wisconsin, Madison
NCT05322954
Data-driven Identification for Substance Misuse
University of Wisconsin, Madison
NCT03833804
Integrating Clinical Practice Guidelines for Smoking Cessation Into Mental Health Care for Veterans With Posttraumatic Stress Disorder
US Department of Veterans Affairs
NCT00118534
Preventing Addiction Related Suicide (PARS)
University of Washington
NCT03166709
Job-Seekers Training for Patients With Drug Dependence - 1
Johns Hopkins University
NCT00102362
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
National Institute on Drug Abuse (NIDA)
NCT00015340
Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders
Columbia University
NCT01690494
Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment
Dartmouth-Hitchcock Medical Center
NCT01457391
Women's Treatment for Trauma and Substance Use Disorders - 1
New York State Psychiatric Institute
NCT00078156
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
National Institute on Drug Abuse (NIDA)
NCT00000318
Motivational Enhancement Therapy to Improve Treatment Utilization in Pregnant Substance Users - 1
University of Cincinnati
NCT00078143
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
National Institute on Drug Abuse (NIDA)
NCT00158288
Helping College Students With ADHD Lead Healthier Lifestyles
University of Maryland, College Park
NCT02829970
Relapse Prevention With Varenicline
Johns Hopkins University
NCT00944554
Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD
Medical University of South Carolina
NCT02755103
Wraparound for High-risk Families with Substance Use Disorders: Examining Family, Child, and Parent Outcomes
Dartmouth-Hitchcock Medical Center
NCT04637581
Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults
Michael J. Wesley, PhD
NCT03944954
Flupenthixol Decanoate in Methamphetamine Smoking - 1
National Institute on Drug Abuse (NIDA)
NCT00000241
Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders
Dartmouth-Hitchcock Medical Center
NCT01457404
Cognitive Therapy for PTSD in Addiction Treatment
Dartmouth-Hitchcock Medical Center
NCT00685451
Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families
We The Village
NCT05875142
We The Village Family Support Study
We The Village
NCT04250077
Quetiapine for Cocaine Use and Cravings
Seattle Institute for Biomedical and Clinical Research
NCT00232336
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
New River Pharmaceuticals
NCT00248092
Pilot Clinical Trial of Computer-based Motivational Intervention - 1
Wayne State University
NCT00230022
Exercise and Treatment-as-usual in Substance Use Treatment Outcomes
University of Wisconsin, Madison
NCT02570360
Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Stanford University
NCT01006707
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
University of Chicago
NCT00000250
Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8
University of Chicago
NCT00000256
A Laboratory Model for Heroin Abuse Medications - 8
New York State Psychiatric Institute
NCT00000273
Modeling Impaired Judgement in Cocaine Abusers - 6
National Institute on Drug Abuse (NIDA)
NCT00015236
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
National Institute on Drug Abuse (NIDA)
NCT00015301
Buprenorphine Maintenance for Opiate Dependence - 6
National Institute on Drug Abuse (NIDA)
NCT00000357
Prepulse Inhibition of Startle in Cocaine Dependence - 7
National Institute on Drug Abuse (NIDA)
NCT00015249
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
National Institute on Drug Abuse (NIDA)
NCT00000358
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 7 |
| Phase 4 | 5 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Substance-Related Disorders Trial Landscape
ClinicalTrials.gov lists 54 US studies indexed under Substance-Related Disorders, and 15 of those are currently open to recruitment — roughly 28% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Substance-Related Disorders shows 12 late-stage studies (Phase 3 and Phase 4 combined) alongside 15 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Substance-Related Disorders is led by National Institute on Drug Abuse (NIDA) with 10 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 54 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Substance-Related Disorders?
PlainTrial tracks 54 US clinical trials for Substance-Related Disorders, of which 15 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Substance-Related Disorders?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.